评估全身与胃肠道组织损伤生物标志物用于GVHD风险分层
研究采用前瞻性标本采集、回顾性盲法评估设计,在19个中心730例新诊断急性GVHD患者中比较全身炎症与胃肠道组织损伤生物标志物对激素反应、严重疾病、6个月非复发死亡和总生存的预测能力。验证队列显示仅含全身炎症标志物的算法AUC为0.57,显著低于含至少1个胃肠道损伤标志物的算法(0.70、0.73、0.79),且需含胃肠道损伤标志物才能预测长期结局。
要点
- 仅含全身炎症标志物的算法AUC为0.57,显著低于含胃肠道损伤标志物的算法。
- 含2个胃肠道损伤标志物的算法在全部终点中预测准确性最高。
- 所有4种算法均可预测短期结局,但长期结局需含胃肠道损伤标志物。
核心结论
- 含胃肠道组织损伤生物标志物的算法在预测急性GVHD长期结局方面优于仅含全身炎症标志物的算法。
研究设计与样本
- 采用前瞻性标本采集、回顾性盲法评估(PRoBE)设计,从19个中心前瞻性收集730例新诊断GVHD患者血清,分为训练队列352例和验证队列378例。
主要发现
- 验证队列中,仅含全身炎症标志物的算法(TNFR1+TIM3)AUC为0.57,显著低于含至少1个胃肠道损伤标志物的算法(TNFR1+ST2为0.70、TNFR1+REG3α为0.73、ST2+REG3α为0.79,所有P<.001)。
- 所有4种算法均能预测短期结局(对全身糖皮质激素的反应和严重GVHD)。
- 需要纳入胃肠道损伤标志物才能预测长期结局如6个月非复发死亡和生存。
- 含2个胃肠道损伤标志物的算法在全部终点中预测准确性最高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We used a rigorous PRoBE (prospective-specimen collection, retrospective-blinded-evaluation) study design to compare the ability of biomarkers of systemic inflammation and biomarkers of gastrointestinal (GI) tissue damage to predict response to corticosteroid treatment, the incidence of clinically severe disease, 6-month nonrelapse mortality (NRM), and overall survival in patients with acute graft-versus-host disease (GVHD). We prospectively collected serum samples of newly diagnosed GVHD patients (n = 730) from 19 centers, divided them into training (n = 352) and validation (n = 378) cohorts, and measured TNFR1, TIM3, IL6, ST2, and REG3α via enzyme-linked immunosorbent assay. Performances of the 4 strongest algorithms from the training cohort (TNFR1 + TIM3, TNFR1 + ST2, TNFR1 + REG3α, and ST2 + REG3α) were evaluated in the validation cohort. The algorithm that included only biomarkers of systemic inflammation (TNFR1 + TIM3) had a significantly smaller area under the curve (AUC; 0.57) than the AUCs of algorithms that contained ≥1 GI damage biomarker (TNFR1 + ST2, 0.70; TNFR1 + REG3α, 0.73; ST2 + REG3α, 0.79; all P < .001). All 4 algorithms were able to predict short-term outcomes such as response to systemic corticosteroids and severe GVHD, but the inclusion of a GI damage biomarker was needed to predict long-term outcomes such as 6-month NRM and survival. The algorithm that included 2 GI damage biomarkers was the most accurate of the 4 algorithms for all endpoints.
引用
- Etra A, Gergoudis S, Morales G, et al. Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification. Blood Adv. 2022. PMID: 35443021. doi:10.1182/bloodadvances.2022007296
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。